KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) EPS (Weighted Average and Diluted) (2016 - 2025)

AbbVie (ABBV) has disclosed EPS (Weighted Average and Diluted) for 14 consecutive years, with $1.02 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 3500.0% to $1.02 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.36, a 1.26% decrease, with the full-year FY2025 number at $2.36, down 1.26% from a year prior.
  • EPS (Weighted Average and Diluted) was $1.02 for Q4 2025 at AbbVie, up from $0.1 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.51 in Q1 2022 to a low of -$0.03 in Q4 2024.
  • A 5-year average of $1.03 and a median of $0.82 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 22500.0% in 2021, then crashed 106.52% in 2024.
  • AbbVie's EPS (Weighted Average and Diluted) stood at $2.26 in 2021, then tumbled by 38.5% to $1.39 in 2022, then plummeted by 66.91% to $0.46 in 2023, then plummeted by 106.52% to -$0.03 in 2024, then soared by 3500.0% to $1.02 in 2025.
  • Per Business Quant, the three most recent readings for ABBV's EPS (Weighted Average and Diluted) are $1.02 (Q4 2025), $0.1 (Q3 2025), and $0.52 (Q2 2025).